PGRN-RIKEN-CALGB 90401 - Genome-wide Pharmacogenomic Study of docetaxel and bevacizumab in Hormone Refractory Prostate Cancer. Homo sapiens
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA298270
下载链接
链接失效反馈官方服务：
资源简介：
The Cancer and Leukemia Group B (CALGB) 90401 trial compared docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer. A genome-wide association study using clinical outcomes and toxicities was conducted on the basis of data from CALGB patients who provided consent for pharmacogenomic studies and usable DNA
创建时间：
2015-10-09
